Hao Jiang

MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial

Hong‐Hu Zhu, Xiaohui Zhang, Ya‐Zhen Qin et al. · Blood · 2013 · 321 citations · Full text

Oral Tetra-Arsenic Tetra-Sulfide Formula Versus Intravenous Arsenic Trioxide As First-Line Treatment of Acute Promyelocytic Leukemia: A Multicenter Randomized Controlled Trial

Hong‐Hu Zhu, Depei Wu, Jie Jin et al. · Journal of Clinical Oncology · 2013 · 177 citations

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission

Xiao‐Jun Huang, Hong‐Hu Zhu, Ying‐Jun Chang et al. · Blood · 2012 · 122 citations · Full text

Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase

Qian Jiang, Lan‐Ping Xu, Dai‐Hong Liu et al. · Blood · 2011 · 82 citations · Full text

Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: A comprehensive large-scale study from a single Chinese center

Ya‐Zhen Qin, Hong‐Hu Zhu, Qian Jiang et al. · Leukemia Research · 2014 · 75 citations

Hematological Malignancy, C-kit Mutations, Oncology +12